Captopril and Hypertension

✍ Scribed by Robert A. Vukovich Ph.D., James R. Knill M.D. (auth.), David B. Case, Edmund H. Sonnenblick, John H. Laragh (eds.)

• Publisher: Springer US
• Year: 1980
• Tongue: English
• Leaves: 236
• Series: Topics in Cardiovascular Disease
• Edition: 1
• Category: Library

✦ Synopsis

This monograph was developed from a collection of papers that were origi­ nally presented at a symposium entitled "Pathogenesis of Hypertension" held at the Henry Chauncy Conference Center, Princeton. New Jersey. These manuscripts were subsequently revised, updated, and reorganized in a manner suitable for this publication. The symposium was planned to stimu­ late interest among investigators and clinicians alike in the potential for a new class of drugs called converting enzyme inhibitors in clinical medicine. The meeting was sponsored by the Squibb Institute for Medical Research, whose pioneering biochemical and pharmaceutical research had led to the development of the first orally active converting enzyme inhibitor. It is hoped that this monograph will cohesively pull together the thesis that the identification, quantification, and containment of the renin factor in hypertension can be a powerful diagnostic and therapeutic strategy in clinical medicine. In addition, the sequence of studies presented in this manuscript will serve to demonstrate how basic biochemical and physio­ logical research produces fundamental and critical information on which subsequent major advances in clinical pharmacology and medicine can be based.

✦ Table of Contents

Front Matter....Pages i-xi
Front Matter....Pages 1-1
Blood Pressure Homeostasis....Pages 3-13
Mechanisms of Hypertension Induced by Electrolyte-Active Steroids....Pages 15-23
The Relationship of the Renal Medulla to the Hypertensive State....Pages 25-38
The Influence of Various Neurological Defects on the Release of Renin in Normal Man....Pages 39-56
Angiotensin as a Determinant of Renal Perfusion and Function....Pages 57-75
Systemic Vascular Resistance....Pages 77-86
Front Matter....Pages 87-87
Physiological, Biochemical, and Immunologic Aspects of Angiotensin-Converting Enzyme....Pages 89-102
Design of New Antihypertensive Drugs....Pages 103-113
Captopril (Capoten®; SQ 14,225) ( d -3-Mercapto-2-methylpropanoyl- l -proline)....Pages 115-135
Toxicologic and Drug Metabolic Studies of SQ 14,225 in Animals....Pages 137-147
Captopril....Pages 149-170
Front Matter....Pages 171-171
The Renin System in High Blood Pressure, from Disbelief to Reality....Pages 173-184
Experiences with Blockade of the Renin System in Human Hypertension Using Converting Enzyme Inhibitor SQ 20,881 and Saralasin....Pages 185-199
The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension....Pages 201-210
Clinical Experience with Blockade of the Renin-Angiotensin-Aldosterone System by an Oral Converting Enzyme Inhibitor (SQ 14,225, Captopril) in Hypertensive Patients....Pages 211-230
Back Matter....Pages 231-236

✦ Subjects

Cardiology